MS 553

Drug Profile

MS 553

Latest Information Update: 22 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Jiangsu MingSight-Relin Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic retinopathy

Most Recent Events

  • 10 Apr 2018 MingSight Pharmaceuticals plans a phase I trial for Lymphocytic Leukemia and Lymphoma in April 2018 , (NCT03492125)
  • 01 Apr 2015 Phase-I clinical trials in Diabetic retinopathy (In volunteers) in Australia (PO) (NCT02406989)
  • 25 Mar 2015 Jiangsu MingSight Pharmaceuticals plans a phase I trial in Healthy volunteers in Australia (NCT02406989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top